Back to search

Article

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancer

2025-10-12

Abstract excerpt

<title>Abstract</title> <p> Immunotherapy with immune checkpoint inhibitor (ICI) improved outcomes in advanced/metastatic melanoma and non-small cell lung cancer (NSCLC), but only a subset of patients benefited significantly. Existing biomarkers like tumor mutational burden (TMB) and microsatellite instability (MSI) had limitations, prompting the search for novel biomarkers. <italic>EYS</italic> , which is pri...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
29bb5f12-d19c-58e2-b2da-38903a1c117a
DOI
10.21203/rs.3.rs-7648150/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerDOI 10.21203/rs.3.rs-7648150/v1
Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor respondersSemantic proximity
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity
Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity
Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.Semantic proximity
A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity
Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsSemantic proximity
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.Semantic proximity
The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity
Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity
HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity
Select a neighboring publication to make it the new centre.